



NEWS RELEASE

BIOSENSORS ANNOUNCES CTO'S RETIREMENT

Singapore, 6 January 2015 – Biosensors International Group, Ltd. ("**Biosensors**" or the "**Company**", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced the retirement of Chief Technology Officer ("CTO") Dr. Jack Wang with effect from 6 January 2015.

Dr. Wang joined Biosensors in 2001 as Vice President for Research & Development and became the Company's CEO in March 2012, having spearheaded its transformation from a small medical device player into an internationally recognized brand. He was succeeded by Mr. Yoh Chie Lu as interim CEO in May 2014 but has continued to serve the Company as CTO.

"Biosensors has been very fortunate to have had Dr. Wang holding the helm for more than a decade. His stewardship helped build the Company into what it is today," said Mr. Gordo, Biosensors' CEO. "He has also provided tremendous support to me during the leadership change over the past few months."

"On behalf of the Board and Management, I would like to thank Dr. Wang for his leadership and significant contributions to Biosensors' development," said Mr. Yoh-Chie Lu, Biosensors' Executive Chairman. "We wish him every success as he pursues other interests following his retirement."

BY ORDER OF THE BOARD

Yoh-Chie Lu
Chairman

###

Media/Investor Relations Contact

Tel: (65) 6213 5777

Email: ir@biosensors.com

About Biosensors International Group, Ltd.

Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, the Company was listed on the Mainboard of the Singapore Stock Exchange in 2005.

The Group currently operates through four business units ("BU"): the Cardiovascular BU, composed primarily of Excel™ and the BioMatrix™ family of drug-eluting stents and stent technologies such as BA9™; the Cardiac Diagnostic BU, including Spectrum Dynamics products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate treatment for patients; the Peripheral Intervention BU, offering solutions for the treatment of patients with peripheral arterial disease; and the Critical Care Products BU, which fosters the development of critical care catheters, hemodynamic monitoring, and related devices used during heart surgery procedures, vascular surgery procedures and intensive care treatment.

The Group has operations worldwide and is headquartered in Singapore.

For more information, please visit www.biosensors.com.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.